Condition: Large Cell Neuroendocrine Carcinoma · Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) · Sponsor: Molecular Partners AG
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
This description comes directly from the study's public registry record.
Medical Director MPAG · +41 44 755 77 00 · info@molecularpartners.com
Always discuss trial participation with your own doctor first.
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| United Theranostics | Glen Burnie, Maryland, United States | Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| United Theranostics | Princeton, New Jersey, United States | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07278479